Package Leaflet: Information for the User
Instanyl 50micrograms/dose nasal spray solution
Instanyl 100micrograms/dose nasal spray solution
Instanyl 200micrograms/dose nasal spray solution
fentanyl
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
Instanyl contains the active substance fentanyl and belongs to a group of strong painkillers called opioids. Opioids work by blocking pain signals to the brain.
Instanyl acts quickly and is used to treat breakthrough pain in adult patients with cancer who are already taking opioid painkillers for their underlying persistent pain. Breakthrough pain is a type of pain that occurs suddenly, in addition to the persistent pain that is being managed with regular opioid painkillers.
Do not use Instanyl
Warnings and precautions
Keep this medicine out of the sight and reach of children and in a safe place to prevent accidental use (see section 5 for further information on storing Instanyl).
Talk to your doctor or pharmacist before starting Instanyl, especially:
Sleep-related breathing disorders
Instanyl may cause sleep-related breathing disorders, including sleep apnoea (pauses in breathing while sleeping) and sleep hypoxemia (low oxygen levels in the blood). Symptoms may include pauses in breathing while sleeping, waking up during the night due to lack of breath, difficulty staying asleep or excessive daytime sleepiness. If you or someone else notices these symptoms, contact your doctor to consider reducing the dose.
It is very important that you contact your doctor immediately if you experience breathing difficulties while being treated with Instanyl.
Talk to your doctor if, while using Instanyl, you:
If you experience repeated nosebleeds or notice nasal discomfort during treatment with Instanyl, you should talk to your doctor, who will consider alternative treatments for your breakthrough pain.
Long-term use and tolerance
This medicine contains fentanyl, an opioid. Repeated use of opioid painkillers can make the medicine less effective (your body gets used to it, which is known as pharmacological tolerance). You may also become more sensitive to pain when using Instanyl. This is known as hyperalgesia. Increasing the dose of Instanyl may continue to relieve pain for a while, but it can also be harmful. If you notice that the medicine is becoming less effective, talk to your doctor. Your doctor will decide whether it is best to increase the dose or gradually reduce your use of Instanyl.
Dependence and addiction
Repeated use of Instanyl can also lead to dependence, abuse and addiction, which can result in a potentially life-threatening overdose. The risk of these side effects may be greater with higher doses and longer use. Dependence or addiction can lead to a loss of control over the amount of medicine you use or how often you use it. You may feel a need to continue using the medicine even if it is no longer relieving your pain.
The risk of dependence or addiction varies from person to person. Your risk of becoming dependent on or addicted to Instanyl may be greater if:
If you notice any of the following symptoms while using Instanyl, it could be a sign of dependence or addiction.
If you notice any of these signs, talk to your doctor to determine the best course of treatment for you, when it is appropriate to stop the medicine and how to do so safely.
Children and adolescents
Instanyl should not be used in children and adolescents under 18 years.
Using Instanyl with other medicines
Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines, including those obtained without a prescription.
Instanyl may affect or be affected by other medicines.
Special care should be taken if you are being treated with any of the following medicines:
However, if your doctor prescribes Instanyl and sedatives, you should limit both the dose and duration of concomitant treatment.
Tell your doctor about all sedatives you are taking and follow their recommendations about the dose carefully. It may be helpful to inform your friends or family to be aware of the signs and symptoms mentioned above. Contact your doctor when you report such symptoms.
Instanyl with food, drinks and alcohol
Do not drink alcohol while being treated with Instanyl, as this may increase the risk of serious side effects.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking any medicine.
Instanyl should not be used during pregnancy, unless you have discussed this with your doctor.
Instanyl should not be used during labour, as fentanyl can cause serious breathing problems in the newborn.
Fentanyl can pass into breast milk and cause side effects in the baby. Do not use Instanyl if you are breast-feeding. You should not start breast-feeding until 5 days after your last dose of Instanyl.
Driving and using machines
You should not drive or use machines while being treated with Instanyl. Instanyl can cause dizziness, drowsiness and blurred vision, which can affect your ability to drive or operate machinery.
Before starting treatment and regularly during treatment, your doctor will also explain what you can expect from using Instanyl, when and for how long you should use it, when you should contact your doctor and when you should stop using it (see also section 2).
Follow the instructions for administration of this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.
The dose of Instanyl is separate from your background treatment for cancer pain.
When you start using Instanyl, your doctor will determine with you the dose that relieves your breakthrough pain.
The initial dose is one 50 microgram spray into one nostril each time you have a breakthrough pain episode. During the dose-titration phase, your doctor may advise you to switch to a higher dose.
If your breakthrough pain is not relieved after 10 minutes, you can use only one more spray for this episode.
In general, you should wait 4 hours before treating another episode of breakthrough pain. In exceptional cases, when a new episode occurs before 4 hours, you can use Instanyl to treat this episode, but you should wait at least 2 hours before doing so. If you regularly experience episodes of breakthrough pain separated by less than 4 hours, you should contact your doctor, as your regular cancer pain treatment may need to be changed.
You can use Instanyl to treat a maximum of four episodes of breakthrough pain per day.
Contact your doctor if you experience more than four episodes of breakthrough pain per day, as your background treatment for cancer pain may need to be changed.
In order to keep track of the number of Instanyl doses used, you should mark the boxes on the child-resistant flip-top cap on the outer carton.
Do not change the dose of Instanyl or your other painkillers yourself. Changes in dose should be made with your doctor.
Instanyl is for nasal use.
Read the instructions for use at the end of this leaflet to learn how to use Instanyl.
If you use more Instanyl than you should or if you think someone has used Instanyl by accident
If you have used more Instanyl than you should, contact your doctor, hospital or emergency service to assess the risk and advise on what to do.
The symptoms of overdose are:
Drowsiness, lethargy, dizziness, decreased body temperature, decreased heart rate, difficulties with coordination of arms and legs.
In severe cases, symptoms of overdose with Instanyl can include coma, sedation, convulsions or severe breathing difficulties (very slow or shallow breathing). An overdose can also cause a brain disorder known as toxic leucoencephalopathy.
If you notice any of these symptoms, you should seek medical help immediately.
Note for caregivers:
If you notice that the person being treated with Instanyl becomes drowsy very quickly, has problems breathing or has difficulties staying awake:
If you think someone has used Instanyl by accident, seek medical help immediately. Try to keep the person awake until the emergency service arrives.
If someone has used Instanyl by accident, they may experience the same symptoms as described above in case of overdose.
If you forget to use Instanyl
If your breakthrough pain continues, you can use Instanyl as prescribed by your doctor. If your breakthrough pain has stopped, do not use Instanyl until your next breakthrough pain episode.
If you stop using Instanyl
You should stop using Instanyl when you no longer have breakthrough pain. However, you should continue using your background painkiller for your cancer pain. If you are in doubt, consult your doctor to confirm the correct dose of your regular painkiller.
You may experience sudden withdrawal symptoms similar to the possible side effects of Instanyl if you stop using Instanyl. If you experience withdrawal symptoms, you should talk to your doctor. Your doctor will assess whether you need medicine to reduce or stop these symptoms.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine may cause adverse effects, although not all people will experience them.
Frequently, adverse effects will disappear or decrease with continued use of the medicine.
Interrupt treatment and contact your doctor, hospital, or emergency service immediately if:
These adverse effects can be very serious.
Other adverse effects observed after using Instanyl:
Frequent(may affect up to 1 in 10 people):
Drowsiness, dizziness even with difficulty maintaining balance, headache, throat irritation, nausea, vomiting, flushing, feeling of intense heat, excessive sweating.
Uncommon(may affect up to 1 in 100 people):
Insomnia, lethargy, muscle convulsions, strange or unpleasant sensation on the skin, alteration of taste, motion-induced dizziness, low blood pressure, severe respiratory problems, nasal bleeding, nasal ulcer, runny nose, constipation, mouth inflammation, dry mouth, skin discomfort, skin itching, fever.
Unknown(frequency cannot be estimated from available data):
Allergic reaction, falls, diarrhea, seizures (epileptic crisis), loss of consciousness, inflammation of arms or legs, seeing or hearing things that are not real (hallucinations), delirium (symptoms may include a combination of agitation, restlessness, disorientation, confusion, fear, seeing or hearing things that do not exist, sleep disorders, nightmares), pharmacological tolerance, drug dependence (addiction), drug abuse (see section 2), fatigue, general malaise, withdrawal syndrome (which may manifest with the appearance of the following adverse effects: nausea, vomiting, diarrhea, anxiety, chills, tremors, and sweating), breathing difficulties.
Cases of patients who have developed a perforation in the nasal septum – the structure that separates the nasal orifices – have also been observed.
Prolonged treatment with fentanyl during pregnancy may cause withdrawal symptoms in the newborn, which can be potentially fatal (see section 2).
You should inform your doctor if you suffer from repeated episodes of nasal bleeding or nasal discomfort.
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
The analgesic contained in Instanyl is very potent and can be fatal in children. Instanyl must be kept out of sight and reach of children. After use, always place the nasal spray in the child-resistant box.
Keep this medicine in a safe place, protected from access by other people. This medicine can cause serious harm and even be fatal for people who use it accidentally or intentionally when it has not been prescribed for them.
Do not use Instanyl after the expiration date shown on the packaging after CAD or EXP. The expiration date is the last day of the month indicated.
Store below 30°C. Keep the nasal spray in a vertical position. Do not freeze. If the Instanyl nasal spray freezes, the device may break. You should check the spray button before use if you are unsure how it has been stored.
Instanyl packages that have exceeded the expiration date or are no longer to be used may still contain enough medication to harm other people, especially children. Medicines should not be thrown away through wastewater or household waste. Any used or unused nasal spray should be disposed of according to local regulations or returned to the pharmacy in the child-resistant box. Ask your pharmacist how to dispose of medicines you no longer need. This will help protect the environment.
Composition of Instanyl
The active ingredient is fentanyl citrate. The content is:
50 micrograms/dose: 1 ml contains fentanyl citrate equivalent to 500 micrograms of fentanyl. One spray (100 microliters) contains 50 micrograms of fentanyl.
100 micrograms/dose: 1 ml contains fentanyl citrate equivalent to 1,000 micrograms of fentanyl. One spray (100 microliters) contains 100 micrograms of fentanyl.
200 micrograms/dose: 1 ml contains fentanyl citrate equivalent to 2,000 micrograms. One spray (100 microliters) contains 200 micrograms of fentanyl.
The other components are sodium dihydrogen phosphate dihydrate, disodium phosphate dihydrate, and purified water.
Appearance of Instanyl and Package Contents
Instanyl is a solution for nasal spray. The solution is transparent and colorless. It is packaged in a brown glass bottle with a dosing pump. The nasal spray is dispensed in a child-resistant box and is available in three different package sizes:
1.8 ml (equivalent to 10 doses), 2.9 ml (equivalent to 20 doses), and 5.0 ml (equivalent to 40 doses).
Only some package sizes may be marketed.
The labeling of the three Instanyl concentrations is differentiated by color:
For 50 micrograms/dose, the labeling is orange.
For 100 micrograms/dose, the labeling is purple.
For 200 micrograms/dose, the labeling is greenish-blue.
Marketing Authorization Holder
Istituto Gentili S.r.l.
Via San Giuseppe Cottolengo 15
20143 Milano
Italy
Manufacturer
Curida AS
Solbærvegen 5
NO-2409 Elverum
Norway
Date of Last Revision of this Leaflet
August 2024
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.
INSTRUCTIONS FOR USE OF INSTANYL NASAL SPRAY
Read the following instructions carefully to learn how to use the Instanyl nasal spray:
Preparing the Instanyl nasal spray for use:
Before using the nasal spray for the first time:
The Instanyl nasal spray should be used as follows:
If after 10 minutes you need a second dose of Instanyl to relieve pain, repeat steps 1 to 8 in the other nostril.
Always keep Instanyl in the child-resistant box after use. Keep out of sight and reach of children.
Keep a record of how many doses you have used and how many you have left in your nasal spray on the dose counter card provided with the Instanyl nasal spray. Each time you use the Instanyl nasal spray, make sure you or your caregiver fill in the information on the card.
If the Instanyl nasal spray is blocked or does not spray correctly: